We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 96

Commission presents preliminary report on potential areas for antitrust investigation in the pharmaceutical sector

  • Hogan Lovells
  • -
  • European Union
  • -
  • December 1 2008

The European Commission's Directorate for Competition (the Commission) has published the preliminary findings from its ongoing inquiry into the pharmaceutical sector

EU daily updates: food consumer policy pharmaceuticals - 301007

  • Hogan Lovells
  • -
  • European Union
  • -
  • October 30 2007

Commission Regulation (EC) No 12752007 of 29 October 2007 amending Annex IX to Regulation (EC) No 9992001 of the European Parliament and of the Council laying down rules for the prevention, control and eradication of certain transmissible spongiform encephalopathies

EU daily updates: foodconsumer policypharmaceuticals - 19112007

  • Hogan Lovells
  • -
  • European Union
  • -
  • November 19 2007

Commission Decision of 8 November 2007 amending Decision 2007102EC adopting the work plan for 2007 for implementation of the programme of Community action in the field of public health (2003 to 2008), including the annual work programme for grants

EU daily update: other developments - 211107

  • Hogan Lovells
  • -
  • European Union
  • -
  • November 21 2007

On November 20, 2007, EU Commissioner for Internal Market and Services Charlie McCreevy has called on national supervisors of financial markets in the EU to become more accountable to authorities and incorporate a European dimension into their mandate

EU daily update: foodconsumer policypharmaceuticals - 131107

  • Hogan Lovells
  • -
  • European Union
  • -
  • November 13 2007

Commission Regulation (EC) No 13232007 of 12 November 2007 amending Annex I to Council Regulation (EEC) No 237790 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin, as regards firocoxib

EU daily update: foodconsumer policypharmaceuticals - 201107

  • Hogan Lovells
  • -
  • European Union
  • -
  • November 20 2007

Decision No 13502007EC of the European Parliament and of the Council of 23 October 2007 establishing a second programme of Community action in the field of health

Schering-Plough secures EC merger clearance for Organon acquisition by agreeing to extensive divesture package

  • Hogan Lovells
  • -
  • European Union
  • -
  • December 6 2007

On October 11, 2007, the European Commission (the Commission), under the EC Merger Regulation, cleared the US Schering-Plough Corporation acquisition of the Dutch Organon BS, after Schering-Plough agreed to divest a substantial portion of the Organon animal health business

Important news for sponsors of ongoing and planned clinical trials about the impact of the EU's Advanced Therapies Regulation

  • Hogan Lovells
  • -
  • European Union
  • -
  • January 25 2008

Companies who are currently conducting, or plan to conduct clinical trials for "tissue engineered products" - including medical devices containing such products - need to examine the EU's new law carefully

The European Commission proposes a much anticipated “pharmaceutical package” governing information for patients, pharmacovigilance and anti-counterfeit measures

  • Hogan Lovells
  • -
  • European Union
  • -
  • December 18 2008

On December 10, 2008 the European Commission published its long-awaited “pharmaceutical package."

U.S. and EU authorities focus attention on competition in pharmaceutical industry

  • Hogan Lovells
  • -
  • European Union, USA
  • -
  • March 25 2008

During the past several years, there has been an increase in antitrust enforcement directed at the pharmaceutical industry, both in the United States and in Europe, primarily focused on conduct by branded pharmaceutical companies that might affect the timing and effectiveness of entry by less costly generic drugs